Plain-English translation of NCT05183035 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether —a newer medication—works better when combined with standard chemotherapy for children and young adults whose leukemia has returned. The study compares two groups: one receiving the new treatment plus chemotherapy, and one receiving chemotherapy alone (followed by different maintenance therapy). Researchers hope this medication will help stop cancer cells from surviving chemotherapy.
Leukemia that comes back after initial treatment is very hard to cure because cancer cells learn to resist chemotherapy. This medication is designed to attack cancer cells in a new way, by restoring the cell's natural self-destruction process. The trial exists to see if adding this approach to standard chemotherapy gives children with relapsed leukemia a better chance of survival.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups. Both groups receive intensive chemotherapy over two 42-day cycles. One group also receives during these cycles; the other does not. After completing these two cycles, you may be eligible for a stem cell transplant, or you may continue with maintenance therapy (additional treatment given in smaller doses) for up to 24 more cycles. Throughout the trial, you'll have regular blood tests and clinic visits to monitor how you're responding and to watch for side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States